Search the Newsreel

Elicio Therapeutics (ELTX) awards 64,643 stock options to R&D and medical chief

Elicio Therapeutics (ELTX) has granted 64,643 stock options to Christopher Haqq, Executive Vice President, Head of R&D, and Chief Medical Officer. The options have an exercise price of $3.20 per share, expire on July 16, 2036, and vest in two 50% tranches on July …

Elicio Therapeutics (ELTX) grants 52,832 stock options to Chief Scientific Officer

Elicio Therapeutics, Inc. (ELTX) has granted 52,832 stock options to its Chief Scientific Officer, Peter DeMuth. The options have an exercise price of $3.20 per share and will expire on July 16, 2036. The shares will vest in two equal installments, 50% on July …

Elicio Therapeutics (ELTX) CEO awarded 186,944 stock options at 3.2000

Elicio Therapeutics (ELTX) CEO, President, and Director Robert Connelly was granted 186,944 stock options at an exercise price of $3.20 per share on July 16, 2026. These options expire on July 16, 2036, and vest in two equal tranches on July 16, 2027, and …

Moti Investments discloses 6.1% stake in Elicio Therapeutics (NASDAQ: ELTX)

Moti Investments LLC has disclosed a 6.1% stake in Elicio Therapeutics, owning 1,408,892 shares of common stock, as reported in a Schedule 13G filing. The investment firm, organized in Saint Kitts and Nevis and based in Dubai, holds sole voting and dispositive power over …

ELTX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical Development - Earnings Power Value

ELTX Forecast — Price Target — Prediction for 2027

Elicio Therapeutics (ELTX) Drops 4.14% as Bearish Momentum Tests Key Support - Quality ETF

Elicio Therapeutics Inc. (NASDAQ: ELTX) Stock Price, News & Analysis

Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)

Grupo Financiero Galicia: Q1 Earnings Snapshot

GGAL Q1 2026 Earnings: EPS Misses Estimates Amid Challenging Argentine Macro Environment - Gross Profit Margin

Earnings call transcript: Grupo Financiero Galicia sees Q1 2026 net income drop 66%

GGAL: Profitability declined in 1Q26 as inflation and volatility persisted, but capital and market shares held firm

Elicio Therapeutics, Inc. 1Q 2026: Net income $(11.8M), EPS $(0.65) — 10-Q Summary

A Look At WEILONG Delicious Global Holdings (SEHK:9985) Valuation After Strong Full Year 2025 Results

Monthly Dividend Stock In Focus: Grupo Financiero Galicia

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?

L'action Publicis Groupe chute de 7,4 % à mi-séance malgré des résultats 2025 solides

Publicis groupe sa : Marqué au fer rouge par son

While insiders own 33% of Elicio Therapeutics, Inc. (NASDAQ:ELTX), individual investors are its largest shareholders with 55% ownership

JPMorgan Raises Grupo Financiero Galicia’s Price Target Amid Favorable Political Developments

Grupo Financiero Galicia Announces Leadership Change at Banco Galicia

Publicis groupe sa : Pourquoi, l'action Publicis s'est brusquement retournée à la baisse, malgré une croissance qui laisse à quai la concurrence

HSBC cuts Grupo Financiero Galicia stake in US$636 million share sale

Grupo Financiero (GGAL) Stock Price, News & Analysis

Major Exit: HSBC Unloads $636M Grupo Financiero Galicia Stake in Massive Secondary Offering

Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Elicio Therapeutics Inc. (ELTX) Live Share Price, Invest From India

WL Delicious Announced 2024 Annual Results

Chinese spicy snacks giant Weilong sees first-half profit rise amid slow economy

Publicis Groupe S.A.: Prévisions et Estimations des Analystes | PUB

WEILONG Delicious Global Holdings Ltd (9985.HK) stock price, news, quote and history

Publicis Groupe S.A. : Ratios de Valorisations, Prévisions des analystes

BILICI-YATIRIM, BLCYT Bilanço

Publicis Groupe S.A.: Objectif de Cours et Consensus des Analystes | PUB | FR0000130577

BILICI-YATIRIM, BLCYT Tarihsel Veriler